Basel, Switzerland 6/30/16—Pharmaceutical industry supplier Lonza has announced the acquisition of Triangle Research Labs (TRL) from PBM Capital. Financial details were not disclosed. TRL provides fresh and cryopreserved hepatocytes and non-parenchymal cells from multiple species, and supporting media and culture systems. “Integrating this business into its primary cell portfolio lays the basis for new product offerings and the entry into new strategic markets,” commented Teun van der Heide, vice president, head of Bioscience Solutions at Lonza. “The acquisition is in line with Lonza’s strategy to continue to develop its life science platform and to expand its global cell biology portfolio.”

The acquisition expands Lonza’s primary cell and cell culture offerings. TRL was launched in 2011 as a joint venture of PBM Capital and the nonprofit Hamner Institutes for Health Sciences to provide contract testing services.